High-Density Lipoprotein Infusions

Kohei Takata; Belinda A Di Bartolo; Stephen J Nicholls

doi:10.1016/j.ccl.2017.12.012

High-Density Lipoprotein Infusions

Cardiol Clin. 2018 May;36(2):311-315. doi: 10.1016/j.ccl.2017.12.012. Epub 2018 Feb 21.

Authors

Kohei Takata¹, Belinda A Di Bartolo¹, Stephen J Nicholls²

Affiliations

¹ South Australian Health and Medical Research Institute, University of Adelaide, PO Box 11060, Adelaide, SA 5001, Australia.
² South Australian Health and Medical Research Institute, University of Adelaide, PO Box 11060, Adelaide, SA 5001, Australia. Electronic address: stephen.nicholls@sahmri.com.

PMID: 29609760
DOI: 10.1016/j.ccl.2017.12.012

Abstract

High-density lipoproteins (HDLs) have presented an attractive target for development of new therapies for cardiovascular prevention on the basis of epidemiology and preclinical studies demonstrating their protective properties. Development of HDL mimetics provides an opportunity to administer functional HDL. However, clinical trials have produced variable results, with no evidence to date that they reduce cardiovascular events. This article reviews development programs of HDL mimetics.

Keywords: Atherosclerosis; Cardiovascular risk; High-density lipoproteins; Lipids.

Publication types

Review

MeSH terms

Biomarkers / blood
Cardiovascular Diseases* / blood
Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / prevention & control
Global Health
Humans
Infusions, Intravenous
Lipoproteins, HDL / administration & dosage*
Morbidity

Substances

Biomarkers
Lipoproteins, HDL